HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MMED

MiniMed Group, Inc. (NASDAQ)

Healthcare — Medical Instruments & Supplies

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.

Strong Buy 1.3 / 5 11 analysts
$15.19
+$0.24 (+1.61%)
Target: $20.91 (37.7%)
Sign in to add MMED to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$4.27B
P/E Ratio (TTM)-
Forward P/E22.30
EPS (TTM)$-1.30
Dividend Yield-
Profit Margin-10.73%
Revenue Growth15.60%
ROE-9.13%
Debt/Equity1.47
Recommendation Strong Buy 1.3
Analyst Target$20.91
Analysts11
Indexes NASDAQ

Technical Indicators

RSI (14)54.7
Beta-
SMA 20-
SMA 40-
52-Week High$20.48
52-Week Low$10.65
50-Day Avg$12.98
200-Day Avg$13.94
Avg Volume950.1K
Volume851.3K

Performance Analysis

BULLISH

MMED shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 46% of its 52-week range.
~ RSI at 54.7 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 15.6% year-over-year.
- Operating at a loss with -10.7% margin.
+ Wall Street consensus is "Strong Buy" from 11 analysts.
+ Average analyst target of $20.91 implies 37.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:20 UTC

Back to Screener Export Report